October 26th 2024
FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.
October 15th 2024
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
Dr. Kim on Combination Therapies in Lung Cancer
September 13th 2016Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.
Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC
September 8th 2016Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.
Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC
September 7th 2016David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).
Expert Highlights Potential of Immunotherapy in Gastric Cancer
August 29th 2016Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.
Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC
August 26th 2016Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).
Expert Says Nivolumab Poised to Change Standard of Care in SCCHN
August 23rd 2016Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.
Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC
August 23rd 2016Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.
Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment
August 21st 2016Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.
Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers
August 16th 2016Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.
Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer
August 15th 2016Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.